- Home
- GRML vs IGC Comparison
GRML vs IGC Comparison
Compare GRML & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRML | IGC |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 32.0M |
| IPO Year | 2022 | 2005 |
Fundamental Metrics
Financial Performance| Metric | GRML | IGC |
|---|---|---|
| Price | $15.32 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.25 |
| AVG Volume (30 Days) | ★ 15.3M | 644.0K |
| Earning Date | 05-13-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.25 | ★ 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $0.24 |
| 52 Week High | $18.21 | $0.45 |
Technical Indicators
Market Signals| Indicator | GRML | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 75.34 | 47.93 |
| Support Level | $0.20 | $0.27 |
| Resistance Level | N/A | $0.31 |
| Average True Range (ATR) | 2.02 | 0.01 |
| MACD | 1.15 | -0.00 |
| Stochastic Oscillator | 80.96 | 36.60 |
Price Performance
Historical ComparisonAbout GRML Greenland Mines Ltd. Common Stock
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.